ArticleBiomedical chromatography : BMC2026
Overcoming Stability Challenge During the Quantification of SHR6508 in Human Plasma by LC-MS/MS.
Article in Biomedical chromatography : BMC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
SHR6508, a novel calcimimetic agent, is currently being developed for treating secondary hyperparathyroidism in chronic kidney disease (CKD) patients requiring maintenance hemodialysis. For the purpose of quantifying SHR6508 in human plasma, a sensitive and reliable LC-MS/MS method was first developed and successfully validated. Since SHR6508 is a disulfide bond-containing peptide, ascorbic acid was supplemented into blood samples during collection to prevent thiol-disulfide exchange reactions. Plasma matrix samples were processed by protein precipitation with a water-acetonitrile solution (1:4, v/v) containing 0.05% formic acid. Chromatographic separation was conducted on an XBridge Peptide BEH C18 column (4.6 × 100 mm, 5.0 μm) under gradient elution with water and methanol, each containing 0.1% trifluoroacetic acid. SHR6508 was quantified by tandem mass spectrometry in positive electrospray ionization using multiple reaction monitoring with transitions of m/z 532.0 → 455.5 for SHR6508 and m/z 537.0 → 456.5 for SHR180296 (isotope-labelled internal standard). The quantification linear range was 1.00-1000 ng/mL. All validation parameters including selectivity, carryover, precision, accuracy, recovery, and matrix effect fell within the predefined acceptance criteria. The stabilization strategy developed in this work may also offer valuable insights for the collection and analysis of other disulfide bond-containing peptide drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.